CYP17A1 and neoplasm: Although AA was found to significantly reduce estradiol and testosterone levels, the AR signaling pathway is not the most critical driver of tumor progression in recurrent EOC, and the authors concluded, similar to breast tumors [75], that the preferred therapy is a combination of CYP17A1 inhibitors (abiraterone) with drugs such as the AR antagonist enzalutamide or fulvestrant [83].